This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Henthorn, R. W. Articles by Pritchett, E. L. Search for Related Content PubMed PubMed Citation Articles by Henthorn, R. W. Articles by Pritchett, E. L.

Circulation, Vol 83, 119-125, Copyright © 1991 by American Heart Association

ARTICLES

Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group

RW Henthorn, AL Waldo, JL Anderson, EM Gilbert, BL Alpert, AK Bhandari, RW Hawkinson and EL Pritchett
Division of Cardiology, Christ Hospital, Cincinnati, Ohio 45219.

Oral flecainide acetate was administered to 34 patients with documented symptomatic paroxysmal supraventricular tachycardia (PSVT) with a double-blind, placebo-controlled, 8-week crossover trial design. PSVT was defined as a regular tachycardia of at least 120 beats/min without evidence of atrioventricular dissociation. The study required considerable patient cooperation. Patients first entered a 4-week qualifying phase followed by a 3-week, open label, flecainide dose- ranging phase. They were then randomized in a blind fashion to receive either placebo or tolerated flecainide dose for an 8-week treatment period and then crossed over after four symptomatic documented episodes of PSVT or at the end of the treatment period. By all efficacy parameters analyzed, flecainide was superior to placebo. Flecainide was associated with an actuarial 79% freedom from symptomatic PSVT events compared with only 15% on placebo at 60 days (p less than 0.001). Of the 34 patients, 29 had recurrence of symptomatic PSVT at least once during the placebo phase; only eight patients had a recurrence during the flecainide phase (p less than 0.001). The median time to the first symptomatic PSVT event was 11 days in the placebo group and greater than 55 days in the flecainide group (p less than 0.001). Likewise, the interval between attacks was a median of 12 days on placebo compared with more than 55 days on flecainide (p less than 0.001). Finally, the flecainide slowed symptomatic PSVT heart rates to 143 +/- 12 beats/min from 178 +/- 12 on placebo (p less than 0.02) in the seven patients who had events in the placebo and flecainide treatment phases.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				E. Delacretaz Supraventricular Tachycardia N. Engl. J. Med., March 9, 2006; 354(10): 1039 - 1051. [Full Text] [PDF]

				E. Ramos and M. E O'Leary State-dependent trapping of flecainide in the cardiac sodium channel J. Physiol., October 1, 2004; 560(1): 37 - 49. [Abstract] [Full Text] [PDF]

				Committee Members, C. Blomstrom-Lundqvist, M. M. Scheinman, E. M. Aliot, J. S. Alpert, H. Calkins, A. J. Camm, W. B. Campbell, D. E. Haines, K. H. Kuck, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias --executive summary: a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) Developed in Collaboration with NASPE-Heart Rhythm Society J. Am. Coll. Cardiol., October 15, 2003; 42(8): 1493 - 1531. [Full Text] [PDF]

				C. Blomstrom-Lundqvist, M. M. Scheinman, E. M. Aliot, J. S. Alpert, H. Calkins, A. J. Camm, W. B. Campbell, D. E. Haines, K. H. Kuck, B. B. Lerman, et al. ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias*--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias) Circulation, October 14, 2003; 108(15): 1871 - 1909. [Full Text] [PDF]

				Committee Members, C. Blomstrom-Lundqvist, M. M Scheinman, E. M Aliot, J. S Alpert, H. Calkins, A.J. Camm, W.B. Campbell, D. E Haines, K. H Kuck, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: A Report of the American College of Cardiology/American HeartAssociation Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines(Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias)Developed in collaboration with NASPE-Heart Rhythm Society Eur. Heart J., October 2, 2003; 24(20): 1857 - 1897. [Full Text] [PDF]

				C. H.F. Cheng, G. D. Sanders, M. A. Hlatky, P. Heidenreich, K. M. McDonald, B. K. Lee, M. S. Larson, and D. K. Owens Cost-Effectiveness of Radiofrequency Ablation for Supraventricular Tachycardia Ann Intern Med, December 5, 2000; 133(11): 864 - 876. [Abstract] [Full Text] [PDF]

				Treatment of Atrial Fibrillation and Paroxysmal Supraventricular Tachycardia With Bidisomide Circulation, October 21, 1997; 96(8): 2625 - 2632. [Abstract] [Full Text]

				L. I. Ganz and P. L. Friedman Supraventricular Tachycardia N. Engl. J. Med., January 19, 1995; 332(3): 162 - 173. [Full Text] [PDF]

				D. M. Roden Risks and Benefits of Antiarrhythmic Therapy N. Engl. J. Med., September 22, 1994; 331(12): 785 - 791. [Full Text]

				E. L.C. Pritchett, E. A. McCarthy, and W. E. Wilkinson Propafenone Treatment of Symptomatic Paroxysmal Supraventricular Arrhythmias: A Randomized, Placebo-Controlled, Crossover Trial in Patients Tolerating Oral Therapy Ann Intern Med, April 1, 1991; 114(7): 539 - 544. [Abstract] [PDF]